ReviewFrontiers in cellular and infection microbiology2019
Biomarkers in Post-kala-azar Dermal Leishmaniasis.
Review in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Ocular Leishmaniasis - A systematic review.Indian journal of ophthalmology · 2021Pooled it
- Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Trial
- Risk factors for post-kala-azar dermal leishmaniasis (PKDL): Challenges in understanding pathophysiology.PLoS neglected tropical diseases · 2026Review
- Post-kala-azar dermal leishmaniasis: insights into underlying pathogenic mechanisms and genetic landscape.Frontiers in microbiology · 2026Review
- How Common Is Imported Cutaneous Leishmaniasis in Romania? Two Case Reports.Microorganisms · 2025Article
- Vaccine efficacy induced by virus-like particles containing Leishmania donovani surface glycoprotein GP63.PLoS neglected tropical diseases · 2024Article
- The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.Pharmaceutics · 2024Review
- Therapeutic potential of rWnt5A in curbingInfection and immunity · 2023Article
- Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis.Vaccines · 2023Article
- Visceral leishmaniasis (kala-azar) caused byProceedings (Baylor University. Medical Center) · 2023Article
- An Overview on Leishmaniasis in Romania: Diagnosis and Therapeutics.Tropical medicine and infectious disease · 2022Review
- Gauging the skin resident Leishmania parasites through a loop mediated isothermal amplification (LAMP) assay in post-kala-azar dermal leishmaniasis.Scientific reports · 2022Article
- Development of Novel Anti-Leishmanials: The Case for Structure-Based Approaches.Pathogens (Basel, Switzerland) · 2022Review
- An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.Acta parasitologica · 2022Article
- Article
- Case report: Diagnosis of visceral leishmaniasis using metagenomic next-generation sequencing and bone marrow smear.Frontiers in cellular and infection microbiology · 2022Article
- [Generalized old world leishmaniasis: first Moroccan case in an immunocompetent adult?]Medecine tropicale et sante internationale · 2021Article
- Development and Clinical Evaluation of Serum and Urine-Based Lateral Flow Tests for Diagnosis of Human Visceral Leishmaniasis.Microorganisms · 2021Article
- A Multi-Country, Single-Blinded, Phase 2 Study to Evaluate a Point-of-Need System for Rapid Detection of Leishmaniasis and Its Implementation in Endemic Settings.Microorganisms · 2021Article
- Molecular Tracking of theFrontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-kala-azar dermal leishmaniasis (PKDL) follows visceral leishmaniasis (VL, kala-azar) in 10-60% of cases. It is characterized by an asymptomatic skin rash, usually starting in the face and consisting of macules, papules, or nodules. Diagnosis is difficult in the field and is often made clinically. There is an extensive differential diagnosis, and parasitological confirmation is preferred particularly when drug treatment is considered. The response to treatment is difficult to assess as this may be slow and lesions take long to heal, thus possibly exposing patients unnecessarily to prolonged drug treatment. Biomarkers are needed; these may be parasitological (from microscopy, PCR), serological (from blood, or from the lesion), immunological (from blood, tissue), pathological (from cytology in a smear, histology in a biopsy), repeated clinical assessment (grading, photography), or combinations. In this paper, we will review evidence for currently used biomarkers and discuss promising developments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.